Vimarsana
Biggest News Aggregation in the World

Page 23 - Accessed March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed March Today - Breaking & Trending Today

Advocates make the case for change in lupus care - Vimarsana News

Advocates make the case for change in lupus care

Improvements with impact: In recognition of World Lupus Day, let’s commit to raise expectations in care and improve the future for people living with lupus.

US FDA Approves GSK's AREXVY, the World's First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults - Vimarsana News

US FDA Approves GSK's AREXVY, the World's First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time The approval is based on data from the positive pivotal AReSVi-006 phase III... | May 3, 2023

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) - Vimarsana News

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an... | May 1, 2023

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Ap - Vimarsana News

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Ap

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer - Vimarsana News

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study...